Jupiros F 160mg/5mg Tablet is a combination lipid-lowering agent containing Fenofibrate 160mg and Rosuvastatin 5mg, indicated for the management of dyslipidemia and mixed hyperlipidemia. Fenofibrate, a fibric acid derivative, primarily reduces triglyceride levels by activating peroxisome proliferator-activated receptor alpha (PPARα), which enhances lipolysis and elimination of triglyceride-rich particles. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) by inhibiting cholesterol synthesis in the liver and upregulating LDL receptors. The synergistic action of these agents results in significant improvement in lipid profiles, including reduction of LDL-C, total cholesterol, triglycerides, and an increase in high-density lipoprotein cholesterol (HDL-C). Jupiros F is indicated for patients with mixed dyslipidemia who have not achieved desired lipid control with monotherapy or lifestyle modifications alone. It is essential to use this medication under medical supervision, with regular monitoring of liver function tests, renal function, and lipid parameters to detect potential adverse effects such as hepatotoxicity, myopathy, or rhabdomyolysis. Lifestyle interventions including diet, exercise, and weight control should be continued during therapy to optimize treatment outcomes.